ARS Pharma to Present Real-World Data on Intranasal Epinephrine at 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting

Core Insights - ARS Pharmaceuticals is presenting real-world data on the effectiveness of neffy® (epinephrine nasal spray) at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology, highlighting that approximately 90% of patients experiencing anaphylaxis were effectively treated with a single dose of neffy [1][2] - The presentations include one late-breaking oral presentation and six poster presentations, showcasing the treatment's value and effectiveness in various clinical settings [1][2] Company Overview - ARS Pharmaceuticals is focused on empowering at-risk patients and their caregivers to manage severe allergic reactions that could lead to anaphylaxis [1][18] - The company is commercializing neffy®, an epinephrine nasal spray indicated for emergency treatment of Type I allergic reactions, including anaphylaxis, in patients aged 4 years and older [1][18] Presentation Details - The oral presentation titled "Real World Data on the Effectiveness of Epinephrine Nasal Spray in Clinical Practice – Update" will take place on November 8, 2025 [3] - Six poster presentations will cover various topics, including the effectiveness of neffy in clinical settings and patient experiences with the nasal spray compared to autoinjectors [5][6][7] Clinical Evidence - Dr. Jonathan Spergel emphasized that the consistency of outcomes across diverse patient populations supports the reliability of intranasal epinephrine, asserting that it is as effective as injections [2] - Case reports presented during the meeting demonstrate the successful use of neffy in patients undergoing oral food challenges and allergy immunotherapy [2][7] Market Context - There are approximately 40 million people in the U.S. experiencing Type I allergic reactions, with a significant number diagnosed with severe reactions that may lead to anaphylaxis [17] - Despite the availability of epinephrine auto-injectors, many patients delay or do not administer treatment during emergencies due to various limitations, highlighting the need for alternatives like neffy [17]